Introduction
Treatment ef®cacy in prostate cancer depends on patient selection at the time of diagnosis. In the case of localized disease, the indications for radical surgery are based on selection criteria de®ned in retrospective studies, including a localized palpable tumor, a PSA level below 20 ngaml, and fewer than two-thirds of positive biopsy specimens 1±4 . The goal of these selection criteria is to reduce the rate of extracapsular disease. However, large prospective, randomized studies are needed to determine whether these selection criteria have an impact on progression-free and speci®c survival. In addition, patient characteristics are changing with time, and the results of previous studies may no longer be relevant to the prediction of postoperative outcome. 5 Large screening studies of prostate cancer have shown that the PSA level is the best diagnostic indicator, and this index has helped with earlier diagnosis 6 . As recently shown at the Baylor Institute, the proportion of organcon®ned disease is falling, mainly because of an increasing number of unpalpable tumors with abnormal PSA levels (Tlc). 5 In this study we examined changes in pathological results since radical prostatectomy became our treatment of choice for prostate cancer until 1996.
Materials and methods
From January 1989 to December 1996, 175 patients with clinically localized prostate cancer underwent bilateral pelvic lymphadenectomy and retropubic or perineal radical prostatectomy at our institution. Preoperative staging was based on digital rectal examination, PSA assay (Hybutech 1 Assay Nl`urgraml), ultrasound-guided transrectal biopsies, bone scan and pelvic CT scan.
The radical prostatectomy specimens were processed and analyzed for extracapsular extension, positive margins, and seminal vesicle invasion according to the Standford protocol. 7 Tumoral volume was calculated for 1994. Tumor staging was achieved using the 1992 TNM classi®cation. Patients were prospectively monitored on the basis of PSA values, and biological progression (PSA b 0.2 ngr/ml) was used as the endpoint for disease recurrence.
PSA values at the time of diagnosis, the Gleason score, tumoral volume, the stage and the postoperative PSA level were compared between each year of our experience. Fisher's test, the Mann±Whitney test and Kaplan± Meier analysis were used for statistical analysis. Differences were considered statistically signi®cant if p`0.05.
Results
Changes in diagnosis and preoperative staging with time Preoperative characteristics of the 175 patients treated for localized prostate cancer in our institution from January 1989 to December 1996 are listed in Table 1 . During this period the patients' average age was 65.5 AE 6.1 y (range 47.6±75.6), the mean PSA value was 20.9 AE 23.4 ng/ml, the mean number of positive biopsies per patient was 1.8 AE 1.4, and the mean Gleason score was 5.7 AE 1.3.
We found no change during the study period in mean age at diagnosis, the mean number of positive biopsies or the Gleason score. However, as shown in Figure 1 and Table 1 , there was a signi®cant fall in the preoperative PSA values between 1989 and 1996, from 52.0 ng/ml to 12.2 ng/ml (P 0.0001). This corresponded to a signi®-cant increase in Tlc tumors, from 13.3% in 1992 to 59.0% in 1995 (P 0.0001), and a fall in Tla-Tlb and T2 tumors from 100±41%, respectively (Table 2 and Figure 2 ).
Surgical results and pathological stage
The mean weight of surgical specimens during the study period was 48.9 AE 21.2 g, and the mean postoperative Gleason score was 6.1 AE 1.4. Tumoral volume was 1.05 AE 1.35 cc3. Sixty-seven percent of tumors were organ-con®ned, 25.1% were extracapsular and 28% had positive surgical margins; the seminal vesicles were positive in 14.8% of cases, and the lymph nodes were positive in 6.2% (Table 3) .
The rate of organ-con®ned disease increased from 40% in 1989 to 81.8% in 1996, and the rate of positive surgical margins fell from 80.0 to 18.5%, respectively ( Figure 3 ).
Changes in postoperative outcome with time
Biological recurrence is a serum PSA level which is detectable postoperatively ( b 0.2 ngr/ml). Biological progression according to the Kaplan±Meier analysis decreased one year after prostatectomy from 60% for (Figure 4 ). It is noteworthy that the surgical approach (retropubic or perineal) did not affect our results.
Discussion
The development of surgical techniques for nerve-sparing radical prostatectomy by Walsh and others has changed the treatment of localized prostate carcinomas in our institution. 8±10 Life expectancy mainly depends on the previous medical history and tumor volume, which remains dif®cult to determine preoperatively. The main pathological risk factors for postoperative progression are capsular invasion and positive surgical margins.
11±16
Numerous teams have attempted to de®ne this risk preoperatively, using a combination of preoperative parameters such as PSA, Gleason grade, and the number of positive biopsy specimens. 4, 17 The real impact of these tests is still unknown, but there is a consensus that radical prostatectomy is the treatment of choice for localized disease in the case of patients with a good life expectancy, when preoperative PSA are less that 20 ngr/ml and Gleason score of prostate biopsies is less than 6. 18, 19 Early diagnosis of signi®cant prostate cancer remains the main goal for a majority of investigators. 20 Screening programs for prostate cancer based on PSA have been extensively developed, giving signi®cant information on abnormal PSA values ( b 4 ng/ml). 21±24 The number of patients with prostate cancer increased and then stabilized in recent years, while mean age at the time of treatment fell. 25 In recent studies, Scardino et al and Catalona et al have found that early diagnosis of prostate carcinoma did not increase the number of insigni®cant tumors. 20, 21 In this present study, preoperative parameters and pathological stage were compared year on year. Like others, we observed a decrease in extracapsular disease Figure 3 Evolution of pathological stage (pT1-pT2) and positive surgical margins. Figure 4 Progression after radical prostatectomy.
Pathological results of a radical prostatectomy L Salomon et al that was not associated with an increase in insigni®cant tumors. 5, 25 Preoperative PSA levels were the only preoperative parameter that changed over the years, probably because the results of large screening studies prompted us to perform transrectal biopsy when PSA levels were above 4 ng/ml. As we obtained better results with this approach, we also started to follow new recommendations on minimizing preoperative bone scans and pelvic CT scans when the PSA is under 10 ng/ml. 26, 27 Our knowledge and practice of radical prostatectomy improved at the same time, with better functional results. 28 
Conclusions
Most analyses of pathological studies and follow-up results in recent years have shown an increase in the proportion of organ-con®ned disease, due mostly to earlier diagnosis of prostate cancer. Like others, we found better results were not associated with an increase in the rate of insigni®cant cancers. Therefore, the period of diagnosis and the PSA level must be included in future studies of preoperative prognostic factors. In addition, additional factors predictive of the risk of extracapsular disease are needed. Given the early diagnosis in most cases, such factors will probably be identi®ed in biological studies of prostate carcinoma.
